NMO Cure? Stem Cell Transplant Offers Hope

Allogeneic hematopoietic cell transplantation (alloHCT) has yielded exceptionally positive results in treating two individuals with neuromyelitis optica (NMO), a severe autoimmune disease. Researchers reported that over 15 years of follow-up, both patients remained relapse-free without ongoing immunosuppression. Their new immune systems demonstrated improved regulation, and disease-driving antibodies permanently disappeared.

Prior to the transplant, patients received chemotherapy to prepare for immune system reset. Donor stem cells were then introduced to rebuild defenses, stopping the attack on astrocyte support cells. While a drastic and risky option, alloHCT has the potential for long-term disease control and possibly a cure in carefully selected patients, especially those intolerant to standard therapies with aggressive, treatment-refractory disease.

One patient has resumed a normal life, with improved neurological function and fathered two children. The other achieved a good quality of life with regained arm function. Despite complications experienced by both patients, which were not definitively linked to the transplant, this study provides the longest follow-up to date for alloHCT in NMO patients, highlighting its promise as an emerging therapeutic route.